![]() ![]() Diarrhea, nausea, vomiting, dermatitis, and deep tiredness have also been described. The most common side effects are mild to moderate pain, swelling and redness at the site of injection, chills, tiredness and headache. The nucleoside-modified RNA vaccine (BNT162b2), which encodes the full-length SARS-CoV-2 spike protein, is the first COVID-19 vaccine approved by the FDA and distributed in the USA. All the symptoms, the time of onset, and duration are summarized in Table Table1 1. This was followed by 3 days without side effects. Nausea manifested without vomiting, started about 1 h after his lunch.īefore the onset of this plethora of symptoms, he only reported low-grade fever and chills the night after the injection. He also reported decreased orientation and awareness of his surroundings. He took ibuprofen and eventually after a long rest, the symptoms, including ophthalmologic manifestation, disappeared. The severity of symptoms was such to require taking a sick leave from work. Hours after the onset of the ocular symptoms, he reported light confusion, asthenia, and profound nausea. The patient, a white adult middle-aged male had no history of ocular problem or migraine, and he had never experienced visual acuity reduction previously. The morning prior to showing visual symptoms, he reported unilateral, oppressive headache, mainly in his parietal to frontal lobe, without associated symptoms (noise or motion sensitivity, osmophobia, photophobia). However, the subjective nature of the ophthalmic symptoms was not better investigated since the symptoms disappeared on the same day and the patient preferred not to undergo instrumental evaluation. After 3 days, on February 5 late morning, he reported a sudden onset of darkening of the visual field, described as subjective reduction of visual acuity associated with visual distortion. Moderna expects to seek emergency authorization late this year or early next after expanding its trial size, while Johnson & Johnson’s clinical trial for kids is still underway.The patient received the 2nd dose of the Pfizer-BioNTech COVID-19 vaccine on the morning of February 2, 2021. So far, the CDC has authorized only the Pfizer-BioNTech vaccine for emergency use in children. “But systems are in place to detect even very rare adverse events.”įirst lady Jill Biden plans to travel around the country in the coming weeks to visit schools and urge parents to get their children vaccinated, NPR reports. “Of course, we always need to keep our eyes open ,” Paul Offit, director of the Vaccine Education Center, a program led by the World Health Organization to provide accurate and up-to-date information about vaccines, told Fortune in an email. The American Academy of Pediatrics has said that there is no evidence that the COVID-19 vaccine leads to a loss of fertility or affects puberty. Around two-thirds of the 1,519 adults surveyed expressed concerns that the vaccine may affect their child’s future fertility. Meanwhile, 30% said they will definitely not get the vaccine for their child. Research by the Kaiser Family Foundation found that 27% of parents are eager to get a vaccine for their younger children. According to the CDC, side effects should go away a few days after receiving the vaccine. Other side effects like diarrhea, joint pain, and vomiting were reported in less than 10% of young children. The study showed no serious side effects, including myocarditis, an inflammation of the heart muscle that occurred extremely rarely in adults after receiving an mRNA vaccine. Fewer than 10% of children experienced fever and muscle pain. After receiving the second dose, 39% of young children experienced fatigue, and 28% reported headaches, compared with 65% and 61% of trial participants ages 16 to 25. Pfizer’s clinical trial showed that the most common was pain at the injection site, similar to vaccine recipients in other age groups. In general, younger kids, who receive a one-third dose of the adult shot, can expect fewer side effects. Another 700,000 have appointments scheduled at major pharmacies like CVS and Walgreens, plus an unknown number who have appointments with pediatricians or at hospitals. In the first week of availability, around 900,000 children received their first doses, or around 3% of those eligible. ![]()
0 Comments
Leave a Reply. |